Brentuximab Vedotin in Combination With Bendamustine for Patients With Hodgkin Lymphoma

Clinical Pearls

Ann S. LaCasce, MD, assistant professor of medicine, Harvard Medical School, lymphoma program, Dana-Farber Cancer Institute, discusses the combination of brentuximab vedotin and bendamustine for the treatment of patients with Hodgkin lymphoma.

• The study analyzed 53 patients with Hodgkin lymphoma who were in first relapse or had primary refractory disease after initial therapy.
• Patients were treated with brentuximab vedotin in combination with bendamustine.
• The overall response rate was 96%.
• 83% of patients achieved a complete remission.
• Some unexpected infusion-related toxicity was observed.

<<<

Go back to the ASH conference page